Published in Clin Exp Rheumatol on May 29, 2012
Role of 2D strain in the early identification of left ventricular dysfunction and in the risk stratification of systemic sclerosis patients. Cardiovasc Ultrasound (2013) 0.85
Text data extraction for a prospective, research-focused data mart: implementation and validation. BMC Med Inform Decis Mak (2012) 0.82
Left ventricular diastolic dysfunction in pulmonary hypertension predicts functional capacity and clinical worsening: a tissue phase mapping study. J Cardiovasc Magn Reson (2015) 0.80
Heart diastolic dysfunction in patients with systemic sclerosis. Arch Med Sci (2014) 0.79
Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans. Medicine (Baltimore) (2014) 0.78
2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2014) 0.77
Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol (2013) 0.76
Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort. Respirology (2017) 0.75
Contractile reserve in systemic sclerosis patients as a major predictor of global cardiac impairment and exercise tolerance. Int J Cardiovasc Imaging (2014) 0.75
Angiogenesis Dysregulation in the Pathogenesis of Systemic Sclerosis. Biomed Res Int (2017) 0.75
Autoimmune myocarditis in systemic sclerosis: an unusual form of scleroderma heart disease presentation. ESC Heart Fail (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 18.52
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr (2009) 14.63
Polymyositis and dermatomyositis (second of two parts). N Engl J Med (1975) 7.26
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet (2007) 5.06
Left ventricular function in scleroderma. Br J Rheumatol (1996) 1.49
Assessment of the right ventricle by echocardiography: a primer for cardiac sonographers. J Am Soc Echocardiogr (2009) 1.35
The heart in scleroderma. Rheum Dis Clin North Am (2008) 1.26
Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis (1973) 1.24
Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis (2007) 1.21
Cardiac involvement in scleroderma. Rheum Dis Clin North Am (1996) 1.21
Cardiac complications of systemic sclerosis. Rheumatology (Oxford) (2009) 1.16
Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis (2009) 1.13
Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum (2008) 1.13
Heart involvement and systemic sclerosis. Lupus (2005) 1.07
Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis (2010) 1.05
Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) (2006) 0.96
Detection of subclinical cardiac involvement in systemic sclerosis by echocardiographic strain imaging. Echocardiography (2008) 0.96
Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve. Ann Rheum Dis (1996) 0.91
The heart in systemic sclerosis. Curr Rheumatol Rep (2004) 0.90
Heart structure and function in systemic sclerosis. Eur J Dermatol (2002) 0.89
Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiogr (2005) 0.88
Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol (2008) 0.86
Detecting subclinical biventricular impairment in scleroderma patients by use of pulsed-wave tissue Doppler imaging. Tex Heart Inst J (2009) 0.84
Evolving focus on diastolic dysfunction in patients with coronary artery disease. Curr Opin Cardiol (2010) 0.82
Tissue Doppler echocardiography and myocardial performance index in patients with scleroderma. J Int Med Res (2005) 0.81
Regional diastolic function by tissue Doppler echocardiography in systemic sclerosis: correlation with clinical variables. Rheumatol Int (2008) 0.81
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol (2012) 4.13
From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A (2008) 3.39
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail (2011) 2.92
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med (2007) 2.86
Skewed genomic variability in strains of the toxigenic bacterial pathogen, Clostridium perfringens. Genome Res (2006) 2.84
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum (2003) 2.20
Clinical problem-solving. Anchors away. N Engl J Med (2007) 2.02
HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus fumigatus. PLoS Pathog (2010) 1.93
Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol (2011) 1.89
Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol (2015) 1.85
Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol (2005) 1.84
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol (2011) 1.82
Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol (2009) 1.80
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol (2004) 1.77
Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol (2009) 1.76
The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem (2006) 1.76
FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med (2014) 1.72
Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem (2001) 1.71
Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken) (2011) 1.67
Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum (2004) 1.65
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum (2002) 1.62
Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum (2006) 1.62
Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2014) 1.61
A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol (2009) 1.60
The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol (2007) 1.57
Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. Am J Physiol Lung Cell Mol Physiol (2009) 1.52
Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum (2011) 1.51
Keratinocyte growth factor expression is suppressed in early acute lung injury/acute respiratory distress syndrome by smad and c-Abl pathways. Crit Care Med (2009) 1.46
Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol (2011) 1.44
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum (2005) 1.42
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail (2013) 1.40
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum (2007) 1.35
Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-γ. Am J Respir Crit Care Med (2011) 1.34
Quorum-sensing control of antibiotic synthesis in Burkholderia thailandensis. J Bacteriol (2009) 1.33
Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol (2008) 1.30
PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One (2010) 1.29
Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol (2012) 1.28
Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol (2009) 1.26
Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol (2003) 1.26
Systemic sclerosis/scleroderma: a treatable multisystem disease. Am Fam Physician (2008) 1.22
Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail (2013) 1.22
Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol (2006) 1.22
Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J (2009) 1.22
Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum (2012) 1.22
The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One (2013) 1.21
Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis). J Pathol (2012) 1.21
Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev (2010) 1.20
Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol (2013) 1.19
Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum (2004) 1.19
Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol (2006) 1.18
Smad3 deficiency ameliorates experimental obliterative bronchiolitis in a heterotopic tracheal transplantation model. Am J Pathol (2004) 1.14
Prognostic value of left ventricular end-systolic volume index as a predictor of heart failure hospitalization in stable coronary artery disease: data from the Heart and Soul Study. J Am Soc Echocardiogr (2008) 1.13
Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res (2005) 1.13
Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum (2005) 1.12
Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun (2007) 1.12
Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol (2012) 1.11
The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep (2013) 1.11
Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. Am J Respir Crit Care Med (2014) 1.11
Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol (2011) 1.10
The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest (2012) 1.10
C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail (2007) 1.10
Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res Ther (2007) 1.09
Association of low-grade albuminuria with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network (HyperGEN) study. Circulation (2013) 1.07
Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol (2005) 1.07
MAP-kinase activity necessary for TGFbeta1-stimulated mesangial cell type I collagen expression requires adhesion-dependent phosphorylation of FAK tyrosine 397. J Cell Sci (2007) 1.06
Coexisting systemic lupus erythematosus and sickle cell disease: a diagnostic and therapeutic challenge. J Clin Rheumatol (2005) 1.06
Elucidation of the functional genomics of antioxidant-based inhibition of aflatoxin biosynthesis. Int J Food Microbiol (2007) 1.05
The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem (2004) 1.05
Identification and characterization of an Aspergillus fumigatus "supermater" pair. MBio (2011) 1.04
Illness and art: the legacy of Paul Klee. Curr Opin Rheumatol (2004) 1.04
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) (2014) 1.03
In perspective: murine models of scleroderma. Curr Rheumatol Rep (2008) 1.03
Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. Am J Cardiol (2011) 1.02
Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther (2010) 1.02
Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol (2005) 1.01
Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology (2006) 1.01
Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am J Cardiol (2013) 1.00
The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am J Pathol (2011) 1.00
The transcriptional cofactor nab2 is induced by tgf-Beta and suppresses fibroblast activation: physiological roles and impaired expression in scleroderma. PLoS One (2009) 1.00
Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. Exp Cell Res (2007) 0.99
Relation of short-term heart rate variability to incident heart failure (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol (2013) 0.98
Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PLoS One (2011) 0.97
Scleroderma-like cutaneous syndromes. Curr Rheumatol Rep (2002) 0.96
Four-dimensional flow assessment of pulmonary artery flow and wall shear stress in adult pulmonary arterial hypertension: results from two institutions. Magn Reson Med (2014) 0.96
Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol (2010) 0.95
Molecular pathways as novel therapeutic targets in systemic sclerosis. Curr Opin Rheumatol (2007) 0.95
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol (2009) 0.95
Right heart structural changes are independently associated with exercise capacity in non-severe COPD. PLoS One (2011) 0.95